DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Remifentanil for the I-gel and Laryngeal Mask Airway Insertion

Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Supraglottic Airways for General Anesthesia

Intervention: remifentanil (Drug); i-gel (Device); laryngeal mask airway (Device); propofol (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Ajou University School of Medicine

Official(s) and/or principal investigator(s):
Jong Yeop Kim, MD, Study Director, Affiliation: Ajou University School of Medicine

Overall contact:
Jong Yeop Kim, MD, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr


Structural differences of supraglottic airway devices could influence the different compressive forces in the oropharyngeal cavities, and require different depth of anesthesia. The addition of remifentanil during propofol anesthesia facilitates the insertion of laryngeal mask airway (LMA) with minimal adverse hemodynamic disturbances. This study was designed to determine the effect-site concentration of remifentanil in 50% of patients (EC50) and 95% of patients (EC95) for successful i- gel insertion, and compare those for LMA insertion during propofol target-controlled infusion (TCI).

Clinical Details

Official title: Comparison of the Effect-site Concentration of Remifentanil for Insertion of the I-gel and Laryngeal Mask Airway During Propofol Anesthesia

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: successful insertion of i-gel and LMA

Detailed description: Anesthesia was induced with propofol TCI at the effect-site concentration of 5 μg/ml, and the predetermined effect-site concentration of remifentanil was started simultaneously. The remifentanil concentration was determined using modified Dixon's up-and-down method (initial concentration: 3. 0 ng/ml, step size: 0. 5 ng/ml). Five minutes later, i- gel or LMA insertion was attempted. The response of the patients to the insertion of LMA was classified as either 'movement' or 'no movement'.


Minimum age: 19 Years. Maximum age: 60 Years. Gender(s): Female.


Inclusion Criteria:

- ASA I-II patients undergoing general anesthesia for short elective surgery (<2 hr)

Exclusion Criteria:

- G-E reflux

- obesity (BMI>30)

- anticipated difficult airway

Locations and Contacts

Jong Yeop Kim, MD, Phone: 82-31-219-5574, Email: kjyeop@ajou.ac.kr

Ajou University hospital, Suwon 443-721, Korea, Republic of; Recruiting
Jong Yeop Kim, MD, Email: kjyeop@ajou.ac.kr
Additional Information

Starting date: March 2015
Last updated: March 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017